A University of Chicago study published in NEJM Evidence found U.S. colorectal cancer rates rose in 2023, reversing a 20-year decline.
Colorectal cancer incidence rates in the United States climbed in 2023, reversing a downward trend that persisted for more than two decades, according to a study published in NEJM Evidence.
The age-adjusted incidence rate stood at 55.2 per 100,000 individuals in 2000, according to data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program cited by DocWireNews. That rate fell to 36.7 per 100,000 in 2022 before ticking upward to 38.3 per 100,000 in 2023.
Researchers at the University of Chicago and partner institutions said that this uptick is the first overall increase recorded since SEER 21 began tracking these metrics in 2000. Investigators observed similar patterns across sex, tumor subsite, diagnosis stage, race, and ethnicity.
“This is the first time that we have seen an increase in the overall rate since in more than 20 years,” said Caitlin Murphy, professor of pediatrics and public health sciences at the University of Chicago.
Screening Age Drop Finds Early Tumors but Misses Older Adult Rise
- Screening Shifts: Lowering the recommended initial screening age from 50 to 45 helped detect more early-stage tumors, particularly in younger cohorts, but does not fully account for rising diagnoses among older adults.
- The Birth Cohort Effect: Epidemiological models suggest that individuals born in the 1960s and later carry an elevated baseline risk that follows them as they age.
- Healthcare Capacity: Rising rates across broader age groups will likely increase demands on oncology clinics, surgical teams, and long-term survivorship care infrastructure.
Incidence Rates Rise Across Age Brackets up to Late Sixties
The study found that age-specific incidence rates increased across multiple brackets up to ages 65 to 69. SciTechDaily reported that the findings indicate the rising trajectory extends well beyond younger adults, who previously drew intense public attention as early-onset colorectal cancer rates climbed.
Murphy explained the epidemiological concept behind the shift in a report by news.uchicago.edu. “I think of a birth cohort effect as the interaction of age and time,” she said. “As people born around the same time move through time and age together, we’re going to see more colorectal cancers being diagnosed.”
The steepest single bracket increase occurred among adults aged 45 to 49, whose incidence grew by 12.76% annually from 2019 to 2023. Researchers attribute this sharp rise largely to expanded screening following updated national guidelines.
“That means that screening is doing as we intend it to do—it’s catching cancer earlier,” Murphy told news.uchicago.edu. However, she said that screening prevalence among eligible adults aged 45 to 49 remains low at roughly 37%, according to separate American Cancer Society data.
| Year | Age-Adjusted Incidence Rate (per 100,000) | 95% Confidence Interval |
|---|---|---|
| 2000 | 55.2 | 54.8 to 55.6 |
| 2022 | 36.7 | 36.4 to 37.0 |
| 2023 | 38.3 | 38.0 to 38.6 |
Pandemic Disruptions Excluded as Primary Driver of 2023 Rise
Investigators analyzed whether disruptions during the COVID-19 pandemic artificially skewed 2023 figures. DocWireNews reported that joinpoint regression models excluded 2020 data based on NCI recommendations.

Even when researchers excluded data from 2020 and 2021, the upward trajectory persisted. Sonia Kupfer, director of the Gastrointestinal Cancer Risk and Prevention Clinic at UChicago Medicine, said that screening had largely rebounded by January 2021, making pandemic disruptions an unlikely primary driver for the 2023 rise.
“These results motivate us to understand reasons for this rise, so risk factors can be identified and possibly reduced,” Kupfer told news.uchicago.edu. Researchers are currently investigating potential environmental chemical exposures alongside established modifiable lifestyle factors such as diet, physical inactivity, and alcohol consumption.
The rising rates among individuals aged 65 to 69, alongside plateaus in the 70 to 74 age group, present an additional puzzle. Because approximately 80% of individuals in these older cohorts remain up to date with routine screenings, investigators suspect that unmeasured environmental or biological risk factors may be offsetting preventive gains.
Future Surveillance and Healthcare Demands
The study authors emphasize that ongoing surveillance through annual cancer registry updates remains vital. The intersection of an aging U.S. population and shifting generational risk profiles points toward substantial growth in future cancer diagnoses.
“Together with age-related acceleration in incidence rates among a large, aging population, a birth cohort effect might result in substantial growth in colorectal cancer diagnoses and increased demand for cancer treatment and survivorship care,” investigators concluded in the study published by NEJM Evidence.
The National Cancer Institute was created on August 5, 1937, when President Franklin D. Roosevelt signed the National Cancer Institute Act, establishing it as a division of the Public Health Service. It became an operating division of the National Institutes of Health in 1944 and gained expanded authority through the National Cancer Act of 1971.
NCI is the oldest and largest of the 27 institutes and centers that comprise the NIH, with a budget of $6.9 billion in 2020. It operates the Surveillance, Epidemiology, and End Results (SEER) program, which supplied the incidence data cited in this study, and supports a nationwide network of 73 NCI-designated Cancer Centers.
References
- Murphy CC, May FP, Kupfer SS et al. Colorectal Cancer among U.S. Adults, 2000-2023. NEJM Evidence. 2026. DOI: 10.1056/evidpha2600217.
- Siegel R et al. Colorectal Cancer Statistics, 2026. CA: A Cancer Journal for Clinicians. 2026.
- National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program.
Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
Related reading
- Daily Tablet Plus Chemo Halts Tumors in 90% in Trial, 8% Undetectable
- Study Finds Azacitidine Kills Leukemia Cells Via RNA, Not DNA
- Aggressive Metastasis-Directed Therapy Does Not Improve Survival in Oligometastatic Breast Cancer, NRG-BR002 Trial Finds (archynewsy.com)
- Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)